Background
==========

The search for novel tools for early diagnosis is one of the major issues in medical research. The discovery of biomarkers in biological fluids and blood is especially challenging due to the tremendous number of biomolecular species, which differ by many orders of magnitude in their relative abundance.[@b1-ijn-5-1005],[@b2-ijn-5-1005] Of the several approaches proposed in the last few years, the study of the proteome seems to hold the greatest potential.[@b2-ijn-5-1005],[@b3-ijn-5-1005] Proteomics is a quickly developing area of biochemical investigation. The basic aim of proteomic analysis is the identification of specific protein patterns from cells, tissues, and biological fluids related to physiological or pathological condition.[@b2-ijn-5-1005],[@b4-ijn-5-1005] It provides a different view from that of gene expression profiling, which does not evaluate post-transcriptional and post-translational modifications, or protein compartmentalization and half-life changes (eg, ubiquitination and proteosome-driven degradation). All these characteristics make the protein profile much more complex but more informative than gene expression profiling. Several approaches can be used to perform proteomic analysis; among these, the most common are methods based on 2D-polyacrylamide gel electrophoresis (2D-PAGE) and mass spectrometry (MS).[@b5-ijn-5-1005]--[@b9-ijn-5-1005]

It is now well accepted that the low-molecular-weight (LMW), low-abundance fraction of biological fluids might contain the most informative source of novel biomarkers. The conventional analytical methods mentioned above do not seem to reach a sufficient degree of resolution and sensitivity to reliably detect and identify LMW and low-abundance peptides. Therefore, research has recently focused on the development of innovative devices that are able to enrich this fraction of body fluid proteome, making it available for use in common analytical tools.

Harvesting and enrichment of candidate biomarkers from complex protein mixtures can be pursued in different ways. Usually, in the plasma or serum, in which albumin and immunoglobulin alone account for \>90% of total protein content, these species are conventionally removed prior to 2D-PAGE and MS by immunoaffinity depletion columns. However, it must be emphasized that many potentially informative biomarkers, represented by very small peptides noncovalently associated with the carrier protein albumin, are lost following this procedure. Many commercial albumin removal kits based on different methods are available, but it has been demonstrated that they can cause loss of several low-abundance proteins, including albuminome.[@b10-ijn-5-1005]--[@b12-ijn-5-1005] Moreover, most of these sieving/filtering systems do not allow sufficient flexibility of the whole process. Therefore, alternative approaches are urgently needed. Nanotechnology methods appear to offer a promising and powerful strategy for overcoming these limitations.[@b13-ijn-5-1005]--[@b16-ijn-5-1005]

Discovered over 40 years ago, porous silicon (PSi) has attracted increasing attention in many fields of research for its interesting features. In particular, the demonstration of its biodegradability in physiological environments has opened up new perspectives for biomedical application.[@b17-ijn-5-1005] The desired dissolution rate can be obtained through the accurate control of the morphology, pore size, and pH. The typical dissolution rate in alkaline conditions ranges from a few minutes to up to a few days. Moreover, the well-known functionalization processes of the porous surface provide further control of bioreactivity and hydrophobicity.[@b18-ijn-5-1005]--[@b21-ijn-5-1005] Various surface derivatization has been reported in the literature and hundreds of different cross-linking agents are now available to selectively bind the target molecules.[@b22-ijn-5-1005]

In this paper, we present a direct approach to harvesting the LMW fraction of a complex solution that relies on 3 important properties of silicon nanoporous nanoparticles (NPNPs): (a) they can act as nanosponges and absorb small molecules depending on nanopore size; (b) they can be separated from solution through efficient centrifugation (the nanoparticle density is higher than that of the solvent); (c) they can be dissolved in water. This last property is relevant because the filtration process can be carried out in physiological solution, without the need for introducing particular solvents, which can contaminate, denaturate, or degrade the potential biomarkers. The whole process is depicted in [Figure 1](#f1-ijn-5-1005){ref-type="fig"} ([Figures 1a--c](#f1-ijn-5-1005){ref-type="fig"} fabrication process and [Figures 1c--h](#f1-ijn-5-1005){ref-type="fig"} harvesting process). The starting solution is incubated with NPNPs which, bcause of size-exclusion, can absorb only the LMW fraction into the nanopore. Afterwards, NPNPs can easily be recovered from solution by means of centrifugation, and resuspended in water, or other solvents in which they can be dissolved. The harvested molecules are then available, in their native state, for further analyses. This easy, cheap, and fast process enables the harvesting of peptides \<13 kDa from raw serum.

Modern biology demands not only fast and easy techniques but also full compatibility with existing protocols. The present approach can be mixed and matched with the majority of current investigation protocols.

Material and methods
====================

NPNPs were fabricated by ultrasonication of a thin film of nanoporous silicon.[@b13-ijn-5-1005]--[@b24-ijn-5-1005] PSi was obtained by anodization of a boron-doped silicon wafer (resistivity 5--10 Ωcm) of \[100\] crystal orientation, using an electrolyte binary mixture of hydrofluoric acid (25%), water (25%), and ethanol (50%). Applied constant current density was 10 mA/cm^2^ for 5 minutes at 25°C. Samples were rinsed in deionized water, then in ethanol and pentane. The PSi film was oxidized in an oven at 200°C for 2 hours. In order to obtain NPNPs, the PSi film was sonicated in dimethylformamide for about 60 minutes and then, after washes in ethanol, ultrasonicated (5 W) in water for 10 minutes at a constant temperature of 4°C, and finally filtered to eliminate impurities \>500 nm.

An ad hoc protein mixture was prepared by mixing 50% (v/v) human serum albumin (MW 66,000 Da; Sigma-Aldrich, St. Louis, Missouri, USA); 30% (v/v) bovine plasma gamma globulin (heavy chain MW 45,000 Da; light chain MW 30,000 Da; Biorad, Berkeley, California, USA); and 20% (v/v) aprotinin (6,500 Da; Sigma-Aldrich). All proteins were dissolved at a concentration of 1 mg/ mL in 100 mM sodium phosphate buffer and 9% (w/v) sodium chloride pH 7.4 (PBC) to reproduce physiological conditions.

Human serum was obtained from a healthy anonymous male donor and collected in accordance with Human Proteome Organization (HUPO) plasma proteome project guidelines.[@b25-ijn-5-1005] Approximately 8 mL of blood were drawn by venipuncture and collected in tubes without additive and allowed to clot at room temperature for 40 minutes. The sample was centrifuged within 2 hours of collection at 1300 × g for 10 minutes, aliquoted into silicon tubes, and stored at −80°C.

Results and discussion
======================

The fabricated NPNPs were deposited onto a glass substrate and characterized using scanning electron microscopy (SEM) and fluorescence microscopy. The results are reported in [Figure 2](#f2-ijn-5-1005){ref-type="fig"}. The pores of the particles are too small to be shown by SEM ([Figures 2 A and B](#f2-ijn-5-1005){ref-type="fig"}), but the typical emission spectrum peak at around 620 nm ([Figures 2C and D](#f2-ijn-5-1005){ref-type="fig"}) indicates a pore size of about 2--3 nm (excitation wavelength 408 nm). The nanoparticle diameter is about 200 nm, and it can be adjusted by changing the power and duration of the sonication process.

We studied the interactions of the nanoparticles with complex biological fluids in different environmental conditions. Here we report 3 experiments with fluids of increasing complexity in order to show the splitting capability of the NPNPs:

1.  *Experiment 1*. Interaction with 1 component solution: small dyes of different MWs.

2.  *Experiment 2*. Interaction of a complex mixture of proteins with a wide range of MWs simulating a biological fluid.

3.  *Experiment 3*. Interaction with crude human serum.

In the first experiment, NPNPs were incubated with 2 solutions of fluorescent polymer of different MWs (6 kDa and 14 kDa dextran-fluorescein isothiocyanate \[FITC\] 10 mg, NPNP 5 mg, water 10 mL, 1 hour). After incubation, the NPNPs were separated from supernatant (centrifugation), dropped on a slide, dried, and analyzed with fluorescence microscopy. The results are summarized in [Figure 3](#f3-ijn-5-1005){ref-type="fig"}. Optical and fluorescence images collected on the NPNPs incubated with polymers of 14 and 6 kDa are reported in upper and lower panels, respectively; for higher MW polymer there is no trace of absorption, and only a weak blue fluorescence coming from salt residue is visible. In contrast, green fluorescence emitted by NPNPs incubated with the lower MW polymer indicates good absorption.

After incubation and centrifugation, the recovered NPNPs can be dissolved in water at a rate depending on the temperature and acidity of the medium. At pH 8 and 90°C, the dissolution takes a few minutes, but it can be also carried out at room temperature in a few hours, if nondenaturing conditions are needed. At pH \<5, the NPNPs do not dissolve, allowing their long-term storage in water at or above room temperature.

In experiment 1, the amount of harvested fraction of dextran-FITC (MW 6 kDa) can be evaluated by comparing the total fluorescence intensity of 2 solutions (harvested vs supernatant). The 2 solutions show very similar fluorescence intensity values, indicating that, under the experimental conditions described above, 50% of the molecules were harvested, whereas the remaining 50% were left in solution. This result shows that the loading capacity is very high, about 1 mg of harvested molecules for each mg of NPNPs.

In the second experiment, the ability of NPNPs to enrich the LMW fraction of a complex mixture was tested with an ad hoc protein mixture (see Materials and methods). For this purpose, the effects of several parameters such as pH, osmolarity, temperature, and incubation time were studied, and conditions were optimized, and, finally, a volume of 200 mL of protein mixture was incubated with 5 mg of NPNPs (about 10^15^ particles) at room temperature for 1 hour. NPNPs were subsequently separated from supernatant by centrifugation, and washed once with PBC buffer. The sodium dodecyl sulfate-PAGE (SDS-PAGE) in [Figure 4](#f4-ijn-5-1005){ref-type="fig"} (panel A) clearly shows that nanoparticles selectively retain small molecules as aprotinin (MW 6,500 Da), whereas proteins with higher MW are completely excluded from the nanopores. We noted that during the incubation a small fraction of the nanoparticles dissolve releasing silicic acid into the solution (about 8% of NPNP volume under our conditions).[@b26-ijn-5-1005] This amount can be decreased by lowering the incubation temperature, pH, or incubation time when possible.

In the third experiment, the same protocol for experiment 2 was applied to raw human serum to demonstrate that NPNPs are able to selectively enrich LMW serum proteome (LMWP). After 1 hour of incubation (100 mL of serum sample diluted 1:2 with PBC buffer, 5 mg of NPNPs), the LMW fraction was recovered by dissolving the nanoparticles in PBC buffer for 12 hours at 37°C. We noted that the dissolution process can be hastened by heating the solution and adding a base (to increase pH) or other solvent. An aliquot of serum, before and after incubation, was analyzed by SDS-PAGE using a 16.5% ready prepared tris-tricine/peptide gel. The efficiency of NPNPs to selectively enrich the LMWP is clearly demonstrated in the SDS-PAGE analysis shown in [Figure 4](#f4-ijn-5-1005){ref-type="fig"} (panel B): in lines 2 and 3, crude human serum and supernatant are represented. In line 4, the LMW fraction of human serum extracted from NPNPs is visible: no molecules \>12 kDa are still present, except for a very small trace of albumin. From densitometric analysis of lane 4, it was estimated that \>50% of total pixel volume was from LMW species, whereas in lane 2 (unprocessed serum) the same area represented \<1% of the total pixel volume. The enrichment factor was thus estimated to be \>50.

In order to characterize the LMW protein species extracted by incubation with NPNPs, gel bands from SDS-PAGE-separated extracts ([Figure 4b](#f4-ijn-5-1005){ref-type="fig"}, lane 4) were cut and processed for tryptic digestion according to the protocol shown in the Supplementary Information, section 1. Based on MW marker information, the 3 processed gel bands corresponded to MW intervals of 15--20 kDa, 10--15 kDa and \<10 kDa. Tryptic peptides were analyzed by nanoscale liquid chromatography interfaced with tandem MS (nanoLC-MS/MS, Supplementary Information, section 2).[@b27-ijn-5-1005],[@b28-ijn-5-1005] In an alternative approach, proteins extracted by incubation with NPNPs were directly digested in solution by trypsin and analyzed by nanoLC-MS/MS. Validated protein identifications are reported in 2 tables (Supplementary Information, section 3). Besides abundant LMW serum proteins, such as apolipoprotein A-II and transthyretin, a database search identified a number of LMW serum proteins that are not considered abundant, such as tetranectin, platelet basic protein, and dermcidin. Furthermore, LC-MS/MS analysis identified several high-MW proteins in the in-gel-digested SDS-PAGE protein bands. Such identifications confirm that the LMW proteome is also populated with fragments of abundant high-MW serum proteins.[@b29-ijn-5-1005]

A comparison of the results of these experiments with those reported in the literature shows many remarkable characteristics of the NPNPs:

1.  easy and cheap production.

2.  controllable pore size and well known surface chemistry.

3.  small molecules can be absorbed with a tuneable MW cut-off.

4.  biocompatibility and biodegradability in physiological solution.

5.  easy recovery by centrifugation,

6.  long-term storage wet (water solution of pH \<5) or dry.

We note that such properties are very attractive also for drug delivery applications, for which the use of nanocarriers is attracting a lot of interest.

Conclusion
==========

We report a straightforward tool relying on water-soluble silicon NPNPs used to harvest the LMW molecules in their native state from a complex fluid. The method is based on the porosity of the nanoparticles, which act as a molecular sieve, and their solubility in a physiological environment. The proposed approach can be mixed and matched with currently available techniques and protocols, and does not require high temperature, denaturing solvents, or other contaminants. A cut-off of about 13 kDa was demonstrated for crude human serum. The ability to tune pore size, combined with the availability of hundreds of biomolecule cross-linkers, opens up new perspectives on complex biofluid analysis, discovery of biomarkers, and in situ drug delivery.

Supplementary information
=========================

In-gel digestion
----------------

Gel bands below 25 kDa were excised and digested by trypsin incubation; selected bands were punched out manually and placed in a silicon Eppendorf tube. Gel pieces were washed once with 150 mL of deionized water and then destained by 3 washes of 150 mL 35% acetonitrile in 25 mM NH4HCO~3~ buffer. After destaining, trypsin digestion was performed overnight at 37°C with modified trypsin (Sigma-Aldrich, St Louis, MO, USA) 0.2 mg/mL. The resulting tryptic peptides were acidified, purified by Ziptips C18 ( Millipore, Billerica, MA) according to the manufacturer's procedure and eluted with 2 μL of a 1:1 mixture of acetonitrile and 0.1% trifluoro acetic acid (v/v). 28 μL of loading pump solvent (see below) were added, and 10 μL were injected for nanoLC-MS/MS analysis.

In-solution digestion
---------------------

Protein extracts were reduced by 2 mM DTT (1 hour at 37°C). 500 ng of sequencing grade modified trypsin (Sigma-Aldrich) were added, and digestion was allowed to proceed for 16 h. The resulting tryptic peptides were fractionated by Off-Gel eletrophoresis before nanoscale LC-MS/MS analysis, in order to achieve a 2-dimensional fractionation of the peptide mixture. An Agilent 3100 Off-Gel fractionator (Agilent Technologies, Santa Clara, CA) was used. Off-Gel isoelectric focusing was essentially peformed according to the manufacturer's instructions. The peptide mixture was diluted with carrier ampholyte mixture (3.6 mL final volume, 10% carrier ampholyte concentration). The sample was then loaded on separate Immobiline^TM^ DryStrip, linear pH range 3.0--10, 18 cm long, purchased from GE Healthcare (Chalfont St. Giles, UK). Peptides were focused at a constant temperature of 20°C, and at constant current intensity of 50 μA. After focusing was complete, fractions were collected. In order to improve peptide recovery, sample wells were washed with 100 μL of a water/methanol/formic acid mixture, 49:50:1 (v/v/v). The wash solution was added to each well and allowed to incubate for 90 minutes before being collected and pooled with the corresponding fraction supernatant. Pooled supernatants were reduced to a volume of approximately 10 μL in a vacuum centrifuge.

A 1:4 mixture of concentrated eluates and loading pump solvent of the nanoLC-MS/MS system (see below) was injected for nanoLC-MS/MS analysis. Considering the injection volume of 10 μL, approximately 1/5 of each OGE fractions was injected for nanoLC-MS/MS.

Nanoscale LC-MS/MS analysis
---------------------------

Chromatography was performed on an Ultimate nanoLC system from Dionex (Sunnyvale, CA, USA), using a valveless setup.[@b30-ijn-5-1005],[@b31-ijn-5-1005] The peptide extracts were redissolved in 30 μL of loading pump solvent (see below) and 10 μL were loaded onto an in-house packed 100 μm i.d., Integra Frit^TM^ (New Objective, Cambridge, MA) trapping column (packing bed length 1.5 cm) at 10 μL/min of loading pump solvent, consisting of H~2~O/acetonitrile/trifluoroacetic acid (TFA) 97.95:2:0.05 (v/v/v). After 4 minutes of column washing, the trapping column was switched on-line to the analytical column: an in-house packed 50 μm i.d., Pico Frit^TM^ column (New Objective), filled with the same stationary phase used for the trapping column packing: 3 μm C~18~ silica particles (Dr Maisch, Entringen, Germany). Peptide separation started at 100 nL/min using a binary gradient. Mobile phase A was H~2~O/acetonitrile/formic acid/TFA 97.9:2:0.09:0.01 (v/v/v/v); mobile phase B was H~2~O/acetonitrile/formic acid/TFA 29.9:70:0.09:0.01 (v/v/v/v). Gradient was from 5 to 45% B in 40 minutes. After 10 minutes at 95% B, the column was re-equilibrated at 5% B for 20 minutes before the following injection.

MS detection was performed on a QSTAR XL hybrid LC-MS/MS from Applied Biosystems (Foster City, CA, USA) operating in positive ion mode, with nESI potential at 1300 V, curtain gas at 15 units, CAD gas at 3 units. Information-dependent acquisition (IDA) was performed by selecting the 2 most abundant peaks for MS/MS analysis after a full TOF-MS scan from 400 to 1600 *m/z* lasting 4 seconds. Both MS/MS analyses were performed in enhanced mode (3 seconds/scan). Threshold value for peak selection for MS/MS was 30 counts.

### Data analysis

MS/MS data were converted to Mascot Generic Format (mgf) by the Analyst software 1.1 (Applied Biosystems). Data were searched on the Mascot search engine ([www.matrixscience.com](www.matrixscience.com)), version 1.9, against the International Protein Index database (IPI version 3_38) using the following parameters: MS tolerance 30 ppm; MS/ MS tolerance 0.2 Da; variable modifications methionine oxidized; enzyme trypsin; max. missed cleavages 1. MS/ MS identifications were validated by using the transproteomics pipeline.[@b32-ijn-5-1005] Peptide identifications with a minimum probability score of 0.7 were retained (4% false discovery rate). Proteins identified with a minimum of 2 peptides were retained (protein probability score \>0.9). Protein identifications based on a single peptide were manually validated.

###### 

Proteins identified by in-gel digestion and nanoLC-MS/MS of SDS-PAGE-isolated bands

  Accession number   Protein description                                                Theoretical Mw   No. unique peptides   Probability   Mascot score\*   Sequence coverage
  ------------------ ------------------------------------------------------------------ ---------------- --------------------- ------------- ---------------- -------------------
  IPI00022434        ALB Uncharacterized protein                                        71.6             45                    1             --               67.5
  IPI00021841        ALB apoliprotein a1                                                30.8             25                    1             --               72.0
  IPI00021885        FGA Isoform 1 of Fibrinogen alpha chain precursor                  94.9             15                    1             --               19.7
  IPI00304273        APOA4 Apolipoprotein A-IV precursor                                45.3             13                    1             --               34.1
  IPI00022371        HRG Histidine-rich glycoprotein precursor                          59.5             11                    1             --               24.8
  IPI00553177        Isoform 1 of Alpha-1-Antitrypsin                                   46.7             10                    1             --               24.2
  IPI00021842        APOE Apolipoprotein E precursor                                    36.1             10                    1             --               36.0
  IPI00783987        C3 Complement                                                      187.0            9                     1             --               4.5
  IPI00399007        IGHG2 Putative uncharacterized protein DKFZp686I04196 (Fragment)   46.0             5                     1             --               14.1
  IPI00419424        IGKV1-5 IGKV1-5 protein                                            26.2             5                     1             --               32.5
  IPI00855916        Transthyretin                                                      15.9             4                     1             --               48.0
  IPI00021855        APOC1 Apolipoprotein C1                                            9.3              3                     0.996         --               24.0
  IPI00032258        Complement c4                                                      192.6            3                     1             --               2.5
  IPI00061977        IGHV3OR16-13;IGHA1 IGHA1 protein                                   54.1             2                     0.999         --               5.0
  IPI00022488        HPX Hemopexin precursor                                            51.6             2                     0.983         --               4.1
  IPI00154742        IGL@ IGL@ protein                                                  24.7             2                     0.999         --               10.7
  IPI00019399        SAA4 Serum amyloid A-4 protein precursor                           14.8             2                     0.998         --               8.5
  IPI00298971        VTN Vitronectin precursor                                          54.2             2                     0.995         --               5.4
  IPI00021857        APOC3 Apolipoprotein C3                                            12.8             1                                   123              16.0
  IPI00021856        APOC2 Apolipoprotein C-II precursor                                11.3             1                                   42               10.0
  IPI00431645        HP protein                                                         31.6             1                                   30               9.0
  IPI00019038        LYZ Lysozyme C precursor                                           16.9             1                                   73               8.0
  IPI00026314        GSN Isoform 1 of Gelsolin precursor                                86.0             1                                   27               1.0
  IPI00298497        FGB Fibrinogen beta chain precursor                                56.5             1                                   43               3.0
  IPI00032328        KNG1 Isoform HMW of Kininogen-1 precursor                          72.3             1                                   34               1.0

**Notes:** In gray, protein identification obtained with a single hit. Those hits were validated by visual inspection. MS/MS data are reported in Supplementary Information. Mascot score (\*) is reported for identifications which have not passed TPP validation, but were above Mascot threshold of 29 and for which manual validation was undertaken.

###### 

Additional proteins identified by direct in-solution digestion of silicon nanopraticle extracts

  Accession number   Protein description                                                              Theoretical Mw   No. unique peptides   Probability   Mascot score\*   Sequence coverage
  ------------------ -------------------------------------------------------------------------------- ---------------- --------------------- ------------- ---------------- -------------------
  IPI00472610        IGHM IGHM protein                                                                52633            16                    1             --               18
  IPI00022229        Apolipoprotein B-100                                                             515.2            16                    1             --               3.6
  IPI00448925        IGHG1 IGHG1 protein                                                              60064            15                    1             --               15
  IPI00478003        A2M Alpha-2-macroglobulin                                                        163175           13                    1             --               10
  IPI00022463        TF Serotransferrin precursor                                                     77.0             13                    1             --               24.5
  IPI00426051        Putative uncharacterized protein DKFZp686C15213                                  51066            10                    1             --               13
  IPI00639937        CFB B-factor, properdin                                                          85.4             9                     1             --               9.7
  IPI00021891        FGG Isoform Gamma-B of Fibrinogen gamma chain                                    51479            8                     1             --               11
  IPI00166866        IGHV3OR16-13; IGHA1 IGHA1 protein                                                53342            8                     1             --               10
  IPI00021857        APOC3 Apolipoprotein C-III                                                       10846            8                     1             --               30
  IPI00382938        IGLV4-3 IGLV4-3 protein                                                          25961            6                     1             --               20
  IPI00022229        APOB Apolipoprotein B-100                                                        515241           5                     1             --               1
  IPI00291262        CLU Clusterin precursor                                                          52.4             4                     1             --               13.8
  IPI00550640        IGHG4 IGHG4 protein                                                              51953            4                     1             --               5
  IPI00328103        KRT27 Keratin, type I cytoskeletal 27                                            49793            3                     1             --               5
  IPI00022418        FN1 Isoform 1 of Fibronectin                                                     262442           3                     1             --               2
  IPI00549291        IGHM IGHM protein                                                                66143            3                     1             --               7
  IPI00217963        KRT16 Keratin, type I cytoskeletal 16                                            51236            3                     1             --               4
  IPI00022431        AHSG cDNA FLJ55606, highly similar to Alpha-2-HSglycoprotein                     46597            3                     1             --               4
  IPI00555872        IGHV3-48 Myosin-reactive immunoglobulin heavy chain variable region (Fragment)   12835            3                     1             --               25
  IPI00021854        APOA2 Apolipoprotein A-II precursor                                              11.1             3                     1             --               21.0
  IPI00022445        PPBP Platelet basic protein precursor                                            13.8             2                     0.999         --               19.5
  IPI00009028        CLEC3B Tetranectin                                                               22.5             2                     0.999         --               10.4
  IPI00029061        SEPP1 Selenoprotein P                                                            42.6             2                     0.999         --               4.7
  IPI00019581        Coagulation factor XII precursor                                                 67.7             2                     1             --               4.4
  IPI00022420        RBP4 Plasma retinol binding protein                                              22.9             2                     0.999         --               10.1
  IPI00027547        DCD Dermcidin precursor                                                          11.3             2                     0.999         --               20
  IPI00017601        CP Ceruloplasmin                                                                 122128           2                     0.999         --               1
  IPI00027718        EVC Ellis-van Creveld syndrome protein                                           111920           2                     0.999         --               1
  IPI00009867        KRT5 Keratin, type II cytoskeletal 5                                             62340            2                     0.999         --               1
  IPI00382488        Ig heavy chain V-III region HIL                                                  13557            2                     0.999         --               13
  IPI00816799        Rheumatoid factor D5 light chain (Fragment)                                      12758            2                     0.999         --               22
  IPI00029739        CFH Isoform 1 of Complement factor H precur                                      139.0            1                     0.992         --               0.9
  IPI00019568        Prothrombin                                                                      69.9             1                     0.986         --               1.6
  IPI00009920        C6 Co (Complement Component 6 Precursor)                                         105.6            1                     0.972         --               1.9
  IPI00298828        APOH Beta-2-glycoprotein 1 precursor                                             38.3             1                     0.907         --               2.6
  IPI00019591        cDNA FLJ55673, highly similar to Complement factor B                             140853           1                     --            45               1
  IPI00008603        ACTA2 Actin, aortic smooth muscle                                                41982            1                     --            41               2
  IPI00411626        FGG Putative uncharacterized protein DKFZp779N0926                               13979            1                     --            42               6
  IPI00382895        UORF                                                                             3952             1                     --            43               29
  IPI00022395        C9 Complement component C9                                                       63133            1                     --            50               1
  IPI00166729        AZGP1 alpha-2-glycoprotein 1, zinc                                               34237            1                     --            65               3
  IPI00382478        Ig heavy chain V-III region TIL                                                  12348            1                     --            86               16
  IPI00384401        Myosin-reactive immunoglobulin kappa chain variable region (Fragment)            11754            1                     --            110              16
  IPI00385252        Ig kappa chain V-III region GOL                                                  11823            1                     --            125              16

**Notes:** In gray, protein identification obtained with a single hit.
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![Pictorial description of the whole process from nanoparticles fabrication to splitting: (a) anodization of silicon wafer to produce porous silicon film; (b) porous silicon film on silicon substrate; (c) nanoporous nanoparticles (NPNPs) fabricated by ultrasonication; (d) incubation of the nanoparticles with biological fluid; (e) centrifugation and wash; (f) supernatant; (g) pellet (physiological solution is added to dissolve it); (h) low-molecular-weight (LMW) harvesting and enrichment is demonstrated on a gel electrophoresis. The middle panel shows a scanning electron microscope image of nanoparticles.\
**Abbreviation:** HMW**,** high molecular weight.](ijn-5-1005f1){#f1-ijn-5-1005}

![Nanoporous nanoparticles characterization. Scanning electron microscope images of nanoporous nanoparticles dried on a slide (panels A and B). The pores of the particles are too small to be shown, but the typical emission spectrum in red-orange band (panels C and D) indicates a pore size of about 2--3 nm (excitation wavelength 408 nm).](ijn-5-1005f2){#f2-ijn-5-1005}

![Optical and fluorescence images of the nanoporous nanoparticles (NPNPs) after incubation with 2 fluorescent polymers of different molecular weights (MWs): dextran-FITC 14 kDa (panels A and B), and dextran-FITC 6 kDa (panels C and D). The adsorption of the lighter polymer is clearly indicated by the green fluorescence emitted from the nanoparticles (panel D). In contrast, no green fluorescence can be observed being emitted from the heavier polymer (the blue fluorescence comes from salt residues), confirming the MW cut-off.](ijn-5-1005f3){#f3-ijn-5-1005}

![(A) The sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of protein mixture before and after incubation with nanoporous silicon particles. 100 mL of protein mixture (see text for details) was subjected to incubation with nanoparticles. Aliquots of the mixture before and after incubation were subjected to tristricine SDS-PAGE and stained with Coomassie Brilliant Blue. Lane 1 A: molecular weight markers; lane 2 A: protein mixture before incubation; lane 3 A: protein mixture following nanoparticle incubation (supernatant); lane 4 A, low-molecular-weight (LMW) protein fraction enriched (pellet). (B) SDS-PAGE analysis of human serum before and after incubation with nanoporous silicon particles. Serum was diluted to 1:2 with 100 mM sodium phosphate buffer, 9% (p/v) sodium chloride, pH 7.4, and incubated with nanoparticles. Aliquots of serum before and after incubation were subjected to tristricine SDS-PAGE and stained with Coomassie Brilliant Blue. Lane 1B, molecular weight markers; lane 2B, crude human serum; lane 3B, human serum following nanoparticle incubation (supernatant); lane 4B, LMW serum fraction enriched using (nondenaturing conditions) nanoporous silicon particles (pellet).](ijn-5-1005f4){#f4-ijn-5-1005}
